AMH ovarian-reserve tests vs fertility prediction

Anti-Müllerian hormone, or AMH, is an ovarian-reserve marker that can help estimate the remaining follicle pool and expected response to ovarian stimulation. It is not an “egg-quality” test or a standalone fertility score. One AMH result cannot independently predict natural conception, time to pregnancy, miscarriage, an exact menopause date, or whether someone can become pregnant.¹²

Ovarian reserve and reproductive potential are different jobs

Ovarian reserve mainly concerns egg quantity and how the ovaries may respond to stimulation. Reproductive potential also depends on age-related egg quality, ovulation, fallopian tubes, uterus, sperm, timing, health and chance. Age remains a stronger predictor of reproductive outcome than AMH alone in many contexts.

This distinction explains how a low AMH result can coexist with natural conception and how a high result cannot guarantee pregnancy. It also explains why a very low value should not automatically be used to deny fertility treatment; ASRM emphasizes that reserve tests are better at predicting oocyte yield than pregnancy potential independent of age.²

The assay and reference context travel with the number

AMH assays are not perfectly harmonized. ACOG notes variability and the lack of an international standard, which limits direct comparisons across laboratories and years.¹ Preserve the laboratory, assay or platform when available, units, reference interval, sample date, age, medicines and reason for testing. Do not chart a trend by copying numbers from different units or assays onto one line.

Hormonal contraception, ovarian surgery, gonadotoxic treatment, PCOS and other clinical factors can affect interpretation. A result ordered during fertility care has a different pretest question from a direct-to-consumer “fertility age” screen.

FDA authorization does not turn AMH into a universal fertility test

FDA authorized the PicoAMH test as an aid in determining menopausal status in specified women, together with clinical and other laboratory findings. FDA explicitly stated it was not cleared or approved to assess fertility status or predict ovarian response to fertility treatment.⁴

That record illustrates intended-use discipline. A laboratory can measure AMH analytically, but a marketing claim such as “predicts your fertility window” is a different assertion requiring its own support. A CLIA certificate concerns laboratory quality requirements; it is not FDA authorization of every clinical interpretation.

Association in IVF is not a natural-conception calculator

A systematic review found AMH associated with cumulative live birth after IVF or ICSI, but association at a group level does not produce an individual guarantee, and the authors noted gaps for natural conception and other settings.³ In assisted reproduction, AMH can influence expectations about ovarian response and retrieved-oocyte numbers; age and the complete treatment pathway still matter for embryos and live birth.

Be cautious with calculators that output a precise percentage without disclosing the development population, assay, age range, missing data, external validation and uncertainty interval. A decimal point can make a model look more certain than its evidence.

A “low” result can create unnecessary urgency

Direct-access testing may turn a biomarker into a countdown. The result can be useful when it prompts a relevant conversation, but pressure to purchase egg freezing, supplements or repeated panels on the same checkout page creates a conflict between interpretation and sale.

Ask the clinician to state what would change if AMH were higher or lower. If the answer is “the same package for everyone,” the test may be functioning as marketing. If a result is unexpected, confirmation strategy and a full reproductive history are more informative than escalating from one number.

A “high” result is not reassurance about every outcome

Higher AMH may occur with a larger follicle pool and in contexts such as PCOS, but it does not diagnose PCOS by itself or prove normal ovulation. In stimulation cycles, a high response can also change medication and safety planning. The interpretation must stay attached to the reason for testing.

Neither direction measures fallopian-tube patency, uterine anatomy or sperm. A complete infertility evaluation is a couple- or person-specific clinical pathway, not an AMH subscription.

Home FSH and AMH should not be collapsed

FSH and AMH are different hormones with different sample types, timing characteristics and intended uses. A home urine FSH strip reports a threshold result and cannot confirm menopause or fertility; the home-FSH guide owns that decision. Ordering both does not automatically create a more accurate “fertility age.” Each result needs a defined question.

1. Name the decision Clarify whether the job is ovarian-stimulation planning, infertility evaluation, menopause assessment or general curiosity.
2. Preserve assay context Record lab, platform, units, reference range, age, medicines and sample date.
3. Translate reserve correctly Treat AMH mainly as a quantity/response marker, not egg quality or pregnancy probability.
4. Demand validated prediction For any score, inspect population, outcome, assay, external validation and uncertainty.
5. Keep commercial offers separate Obtain independent interpretation before purchasing repeated tests, supplements or procedures based on one value.

AMH becomes more useful when its claim becomes smaller. It can inform a defined ovarian-reserve question; it should not carry the emotional and clinical weight of a universal fertility verdict.